English speaker 3. Type 2 diabetes mellitus, regardless of background insulin use Exclusion Criteria: 1.
Known contraindication to bumetanide, eplerenone, or dapagliflozin. Myocardial infarction, unstable angina, stroke or transient ischemic attack TIA within 12 weeks prior to enrollment. HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic obstructive cardiomyopathy or uncorrected primary valvular disease.
Type 1 Diabetes Mellitus (DM) – Endocrinology - Lecturio
Type 1 diabetes mellitus 7. Symptomatic bradycardia or second or third-degree heart block without a pacemaker. Evidence of secondary cause of hypertension e.
Women who are pregnant, breast feeding or of childbearing potential and are not using and do not plan to continue using medically acceptable form of contraception throughout the study pharmacological or barrier methods. Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.
Participant's responsible primary care or other responsible physician believes it is not appropriate for participant to participate in the study. Inability or unwillingness to provide written informed consent. Receiving current treatment with sulfonylureas.
Unable to complete study procedures.